Emyria Ltd has released a press release.
June 2023 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Emyria
- Emyria Recruits First Patient MDMA-Assisted Therapy Trial
- Presentation - Pax Acquisition and Company Update
- Pax Centre Acquisition to Advance Psychedelic Therapies
- Emyria hails ethics approval for MDMA-assisted clinical trial
- Emyria Receives Ethics Approval for MDMA-assisted Therapy
Later from Emyria
- Emyria advances development and commercialisation of unique drug products
- Emyria Launches Ketamine-Assisted Therapy Program
- Appendix 4E Preliminary Financial Report
- Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer
- Prospectus
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria